Literature DB >> 24361057

Long-term outcomes in idiopathic nephrotic syndrome: from childhood to adulthood.

Piotr Skrzypczyk, Malgorzata Panczyk-Tomaszewska, Maria Roszkowska-Blaim, Zofia Wawer, Beata Bienias, Malgorzata Zajgzkowska, Katarzyna Kilis-Pstrusinska, Anna Jakubowska, Marta Szczepaniak, Monika Pawlak-Bratkowska, Marcin Tkaczyk.   

Abstract

BACKGROUND: The aim of the study was to assess idiopathic nephrotic syndrome (INS) relapse rate, co-morbidities, and social status of adults diagnosed with INS in childhood.
MATERIAL AND METHODS: A written questionnaire was sent to 118 adults treated for INS in childhood. In 61 (51.7%) responders (aged 26.0 ± 6.2 years, range 18 - 51.5 years), we used available medical records to evaluate age at the onset of INS, number of INS relapses below 18 years of age, response to corticosteroids (CS), renal biopsy findings, and immunosuppressive treatment as well as questionnaire to evaluate the number and treatment of INS relapses above 18 years of age, co-morbidities, age at menarche, marital status, offspring, educational status, and occupation.
RESULTS: In the group of 61 responders, median age at the onset of INS was 3 (range 1.3 - 14.0) years, median number of INS relapses at < 18 years of age was 5 (1 - 20). Steroid-sensitive nephrotic syndrome (SSNS) was diagnosed in 37 (60.7%) patients, steroid-dependent nephrotic syndrome SDNS in 18 (29.5%) patients, and steroid-resistant nephrotic syndrome (SRNS) in 6 (9.8%) patients. Mesangial proliferation was the most common pattern in renal biopsy (35.7%). All patients received CS, 15 were treated with methylprednisolone pulses, 13 with cyclophosphamide, 11 with chlorambucil, 2 with cyclosporine, and 21 with levamisole. All patients achieved remission and had normal renal function at the age of 18. In adulthood, INS relapsed in 10 (16.4%) patients, including 5 (13.5%) patients with SSNS, 4 (22.2%) with SDNS, and 1 (16.7%) with SRNS (p = 0.72). Median number of relapses was 2 (range 1 - 11). Patients with relapses at > 18 years of age had more (p < 0.005) relapses at < 18 years of age. Hypertension was diagnosed in 8 (16.1%), overweight in 14 (23.0%), obesity in 3 (4.9%), and bone fractures in 12 (19.7%) patients. Five patients had height < 3rd percentile, including 4 with INS onset at < 3 years of age. One patient had growth retardation before the treatment. No myocardial infarctions, strokes, severe infections, or malignancies were reported. Mean age at menarche was 12.9 ± 1.4 years, 37 (60.7%) patients were in a steady relationship/ married, 1/18 (5.6%) patients treated with cytostatic agents and 12/43 (24/7%) patients not treated with cytostatic agents had offspring (p < 0.05). Elementary education was reported by 4 (6.6%), secondary education by 32 (52.5%), and higher education by 25 (40.9%) patients, and 34 (55.7%) patients were professionally active. None of the 6 patients with SRNS developed end-stage renal disease.
CONCLUSIONS: 1. High number of INS relapses in childhood is a risk factor for recurrences in adulthood. 2. INS relapses in childhood do not preclude active professional life in adulthood.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24361057     DOI: 10.5414/CN108044

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  14 in total

1.  Childhood onset steroid-sensitive nephrotic syndrome continues into adulthood.

Authors:  Trine Korsgaard; René Frydensbjerg Andersen; Shivani Joshi; Søren Hagstrøm; Søren Rittig
Journal:  Pediatr Nephrol       Date:  2018-11-13       Impact factor: 3.714

2.  Bone health in children and adolescents with steroid-sensitive nephrotic syndrome assessed by DXA and QUS.

Authors:  Gabriella Aceto; Olinda D'Addato; Giovanni Messina; Vincenza Carbone; Luciano Cavallo; Giacomina Brunetti; Maria Felicia Faienza
Journal:  Pediatr Nephrol       Date:  2014-06-07       Impact factor: 3.714

Review 3.  IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome.

Authors:  Agnes Trautmann; Olivia Boyer; Elisabeth Hodson; Arvind Bagga; Debbie S Gipson; Susan Samuel; Jack Wetzels; Khalid Alhasan; Sushmita Banerjee; Rajendra Bhimma; Melvin Bonilla-Felix; Francisco Cano; Martin Christian; Deirdre Hahn; Hee Gyung Kang; Koichi Nakanishi; Hesham Safouh; Howard Trachtman; Hong Xu; Wendy Cook; Marina Vivarelli; Dieter Haffner
Journal:  Pediatr Nephrol       Date:  2022-10-21       Impact factor: 3.651

4.  Glucose metabolism disorders in children with refractory nephrotic syndrome.

Authors:  Toshiyuki Takahashi; Takayuki Okamoto; Yasuyuki Sato; Asako Hayashi; Yasuhiro Ueda; Tadashi Ariga
Journal:  Pediatr Nephrol       Date:  2020-01-16       Impact factor: 3.714

5.  Report of novel genetic variation in NPHS2 gene associated with idiopathic nephrotic syndrome in South Indian children.

Authors:  Mohanapriya Chinambedu Dhandapani; Vettriselvi Venkatesan; Nammalwar Bollam Rengaswamy; Kalpana Gowrishankar; Sudha Ekambaram; Prabha Sengutavan; Venkatachalam Perumal
Journal:  Clin Exp Nephrol       Date:  2016-01-28       Impact factor: 2.801

6.  Predictability of Urinary CD80 in the Relapse of Primary Nephrotic Syndrome.

Authors:  Juan Liao; Xiao-Chuan Wu; Qia Cheng; Can-Lin Li; Zhu-Wen Yi; Yan Cao; Lan-Jun Shuai
Journal:  Biomed Res Int       Date:  2017-08-29       Impact factor: 3.411

7.  Long-term health-related quality of life outcomes of adults with pediatric onset of frequently relapsing or steroid-dependent nephrotic syndrome.

Authors:  Vincent Audard; Hélène Mellerio; Marie-Sophie Meuleman; Sophie Guilmin-Crépon; Aurélie Hummel; Eric Daugas; Agnès Dumas; Fallou Leye; Jacques Dantal; Claire Rigothier; François Provot; Dominique Chauveau; Stéphane Burtey; Alexandre Hertig; Karine Dahan; Antoine Durrbach; Claire Dossier; Alexandre Karras; Dominique Guerrot; Vincent Esnault; Philippe Rémy; Ziad A Massy; Isabelle Tostivint; Marie-Pascale Morin; Philippe Zaoui; Olivier Fritz; Moglie Le Quintrec; Alain Wynckel; Aurélie Bourmaud; Olivia Boyer; Dil Sahali; Corinne Alberti
Journal:  J Nephrol       Date:  2021-07-05       Impact factor: 3.902

Review 8.  Long-term Outcomes of Childhood Onset Nephrotic Syndrome.

Authors:  Rebecca Hjorten; Zohra Anwar; Kimberly Jean Reidy
Journal:  Front Pediatr       Date:  2016-05-25       Impact factor: 3.418

9.  REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study- protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study.

Authors:  A M Schijvens; E M Dorresteijn; N Roeleveld; R Ter Heine; J A E van Wijk; A H M Bouts; M G Keijzer-Veen; N C A J van de Kar; L P W J van den Heuvel; M F Schreuder
Journal:  BMJ Open       Date:  2017-09-27       Impact factor: 2.692

10.  Incidence of Pneumocystis jirovecii and Adverse Events Associated With Pneumocystis Prophylaxis in Children Receiving Glucocorticoids.

Authors:  Matthew L Basiaga; Michelle E Ross; Jeffrey S Gerber; Alexis Ogdie
Journal:  J Pediatric Infect Dis Soc       Date:  2018-12-03       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.